PMV Pharmaceuticals
PMVPPMV Pharmaceuticals is a clinical-stage precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies that target p53 mutations.
$66.13M+0.2%
Table of contents
Earnings
Next report
Aug 6, 2026 (In 3 weeks)EPS estimate-$0.38
Competitors
By market cap
By revenue growth
Profile
PMV Pharmaceuticals is a clinical-stage precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies that target p53 mutations. The company's platform leverages decades of research to create therapies that structurally correct mutant p53 proteins to restore their natural tumor-suppressing function.
Competitive position
A pioneer in p53 biology with a first-in-class lead candidate targeting the Y220C mutation.
GeographiesUnited States, Global
Customer segmentsOncology patients, Specialist healthcare providers
Business modelR&D intensive, Biopharmaceutical development
SuppliersContract manufacturing organizations (CMOs), Contract research organizations (CROs), Genomic sequencing providers, Raw material suppliers
CustomersSpecialist oncologists, Hospitals, Cancer treatment centers
CountryUnited States of America
Listed2020
Employees63.0
CEODavid H. Mack
SectorHealthcare
IndustryBiotechnology
Websitepmvpharma.com
FilingsSEC EDGAR
Questions, answered.
- What is PMV Pharmaceuticals's market cap?
- PMV Pharmaceuticals (PMVP) has a market capitalization of $66.1M and trades on NASDAQ.
- Who are PMV Pharmaceuticals's competitors?
- PMV Pharmaceuticals's key competitors include Eli Lilly and Company, Novartis, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does PMV Pharmaceuticals partner with?
- PMV Pharmaceuticals's notable partners include Foundation Medicine, Inc..
- Where is PMV Pharmaceuticals headquartered?
- PMV Pharmaceuticals is headquartered in United States of America and employs approximately 63 people. It has been publicly traded since 2020.